Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin

Laboratory Investigation

Volumn 79, Issue 10, 1999, Pages 1261-1269

  Di Carlo, Emma ^a   Diodoro, Maria Grazia ^a   Boggio, Katia ^b   Modesti, Andrea ^c   Modesti, Mauro ^c   Nanni, Patrizia ^d   Forni, Guido ^b   Musiani, Piero ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CYCLINE; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, LOBULAR; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RATS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0032849649     PISSN: 00236837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Anderson EL (1992). Cancer risk assessments: An overview. In: Zervos C, editor. Oncogene and transgenic correlates of cancer risk assessments. New York: Plenum Press, 1-20.
2. Berx G, Cleton-Jansen AM, Nollet F, de Leeuw WJF, van de Vijver MJ, Cornelisse C, and van Roy F (1995). E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107-6115.
3. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, and Forni G (1998). Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589-596.
4. Bouchard L, Lamarre L, Tremblay PJ, and Jolicoeur P (1989). Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 57:931-936.
5. 3 for angiogenesis. Science 264:569-571.
6. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79:1157-1164.
7. Carbone A and Vecchio FM (1985). Presence of cytoplasmic progesterone receptors in hepatic adenomas: Report of two cases. Am J Clin Pathol 85:325-329.
8. Cardiff RD (1998). Are the TDLU of the human the same as the LA of mice? J Mammary Gland Biol Neoplasia 3:3-5.
9. Cardiff RD, Sinn E, Muller W, and Leder P (1991). Transgenic oncogene mice: Tumor phenotype predicts genotype. Am J Pathol 139:495-501.
10. Czubayko F, Liaudet-Coopman EDE, Aigner A, Tuveson AT, Berchem GJ, and Wellstein A (1997). A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med 3:1137-1140.
11. Di Giovanna MP, Carter D, Flynn SD, and Stern DF (1996). Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. Br J Cancer 74:802-806.
12. Di Giovanna MP, Lerman MA, Coffey RJ, Muller WJ, Cardiff RD, and Stern DF (1998). Active signalling by Neu in transgenic mice. Oncogene 17:1877-1884.
13. Du Toit RS, Locker AP, Ellis IO, Elston CW, Nicholson RI, and Blarney RW (1989). Invasive lobular carcinomas of the breast: The prognosis of histopathological subtypes. Br J Cancer 60:605-609.
14. Eusebi V, Pich A, Macchiorlatti E, and Bussolati G (1977). Morpho-functional differentiation in lobular carcinoma of the breast. Histopathology 1:301-314.
15. Folkman J, Watson K, Ingber D, and Hanahan D (1989). Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61.
16. Guy CT, Cardiff RD, and Muller WJ (1996). Activated neu induces rapid tumor progression. J Biol Chem 271:7673-7678.
17. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, and Muller W (1992). Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582.
18. King CR, Kraus MH, and Aaronson SA (1985). Amplification of a novel v-erbB-related gene in human mammary carcinoma. Science 229:974-976.
19. Kordon EC, Molinolo AA, Pasqualini CD, Charreau EH, Pazos P, Dran G, and Lanari C (1993). Progesterone induction of mammary carcinomas in BALB/c female mice: Correlation between progestin dependence and morphology. Breast Cancer Res Treat 28:29-39.
20. Lesser ML, Rosen PP, Senie RT, Duthie K, Menendez-Botet C. and Schwartz MK (1981). Estrogen and progesterone receptors in breast carcinoma: Correlations with epidemiology and pathology. Cancer 48:299-309.
21. Lucchini F, Sacco MG, Hu N, Villa A, Brown J, Cesano L, Mangiarini L, Rindi G, Kindl S, Sessa F, Vezzoni P, and Clerici L (1992). Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTV-Neu transgenic mice. Cancer Lett 64:203-209.
22. Muller WJ, Sinn E, Wallace R, Pattengale PK, and Leder P (1988). Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115.
23. Munn RJ, Webster M, Muller WJ, and Cardiff RD (1995). Histopathology of transgenic mouse mammary tumors (a short atlas). Semin Cancer Biol 6:155-158.
24. Murad TM (1971). Ultrastructure of ductular carcinoma of the breast (in situ and infiltrating lobular carcinoma). Cancer 27:18-28.
25. Nesland JM, Holm R, and Johannessen JV (1995). Ultrastructural and immunohistochemical features of lobular carcinoma of the breast. J Pathol 145:39-52.
26. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, and Hanahan D (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93:2002-2007.
27. Parkin DM, Pisani P, and Ferlay J (1999). Global cancer statistics. CA Cancer J Clin 49:33-64.
28. Pazos P, Lanari C, Elizalde P, Montecchia F, Charreau EH, and Molinolo AA (1998). Promoter effect of medroxyprogesterone acetate (MPA) in N-methyl-nitrosourea (MNU) induced mammary tumors in BALB/c mice. Carcinogenesis 19:529-531.
29. Piffanelli A, Fumero S, Pelizzola D, Berruto GP, Ricci L, and Giovannini G (1982). Protocollo del metodo con Charcoaldestrano (DCC) per il dosaggio del recettori dell'estradiolo e del progesterone nel tessuto neoplastico. LAB J Res Lab Med IX:13-21.
30. Porter PL, Garcia R, Moe R, Corwin DJ, and Gown AM (1991). C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia. Cancer 68:331-334.
31. Querzoli P, Albonico G, Ferretti S, Rinaldi R, Beccati D, Corcione S, Indelli M, and Nenci I (1998). Modulation of biomarkers in minimal breast carcinoma: A model for human breast carcinoma progression. Cancer 83:89-97.
32. Rak J and Kerbel RS (1997). bFGF and tumor angiogenesis: Back in the limelight? Nat Med 3:1083-1084.
33. Rosai J (1996). Breast carcinoma. In: Rosai J editor. Ackerman's surgical pathology, 8th ed. St. Louis: Mosby, 1590-1626.
34. Rosen PP and Oberman HA (1993). Tumors of the mammary gland. In: Rosai J, editor. Atlas of tumor pathology. Washington, DC: Armed Forces Institute of Pathology, 120-132.
35. Russo IH and Russo J (1996). Mammary gland neoplasia in long-term rodent studies. Environ Health Perspect 104:938-967.
36. 3 integrins in hemostasis and vascular biology. Thromb Haemost 74: 149-155.
37. Shousha S, Backhous CM, Alaghband-Zadeh J, and Burn I (1986). Alveolar variant of invasive lobular carcinoma of the breast. Am J Clin Pathol 85:1-5.
38. Siegel PM, Dankort DL, Hardy WR, and Muller WJ (1994). Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14: 7068-7077.
39. Siitonen SM, Kononem JT, Helin HJ, Rantala IS, Holli KA, and Isola JJ (1996). Reduced E-cadherin expression is associated with invasiveness and unfavourable prognosis in breast cancer. Am J Clin Pathol 105:394-402.
40. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, and McGuire WL (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-181.
41. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, and Press MF (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712.
42. Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, Yamada Y, Toyoshima K, and Yamamoto T (1990). Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659 - Glu659). EMBO J 9:181-190.
43. Takeichi M (1991). Cadherin cell adhesion receptors as a morphogenetic regulator. Science 251:1451-1455.
44. Vecchi A, Garlanda C, Lampugnani MG, Resnati M, Matteucci C, Stoppacciaro A, Schnurch H, Risau W, Ruco L, and Mantovani A (1994). Monoclonal antibodies specific for endothelial cells of mouse blood vessels: Their application in the identification of adult and embryonic endothelium. Eur J Cell Biol 63:247-254.
45. Vos CBJ, Cleton-Jansen AM, Berx G, de Leeuw WJF, ter Haar NT, van Roy F, Cornelisse CJ, Peterse JL, and van de Vijver MJ (1997). E-cadherin inactivation in lobular carcinoma in situ of the breast: An early event in tumorigenesis. Br J Cancer 76:1131-1133.
46. Zschiesche W, Schînborn I, Behrens J, Herrenknecht K, Hartveit F, Lilleng P, and Birchmeier W (1997). Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17:561-568.